SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-Q

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES
REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended

Sep 30, 2024

2. SEC Identification Number

148022

3. BIR Tax Identification No.

000-288-655-000

4. Exact name of issuer as specified in its charter

Euro-Med Laboratories Phil., Inc.

5. Province, country or other jurisdiction of incorporation or organization

Metro Manila

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

PPL Building, United Nations Avenue corner San Marcelino St., Manila Postal Code 1007

8. Issuer's telephone number, including area code

00-63-2-85240091/98

9. Former name or former address, and former fiscal year, if changed since last report

N/A

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares	4,112,140,540

11. Are any or all of registrant's securities listed on a Stock Exchange?

Yes

No

If yes, state the name of such stock exchange and the classes of securities listed therein:

The Philippine Stock Exchange, Inc.

12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports)

Yes

No

(b) has been subject to such filing requirements for the past ninety (90) days

Yes

No

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Euro-Med Laboratories Phil., Inc.EURO

PSE Disclosure Form 17-2 - Quarterly Report References: SRC Rule 17 and
Sections 17.2 and 17.8 of the Revised Disclosure Rules

For the period ended	Sep 30, 2024
Currency (indicate units, if applicable)	PHP

Balance Sheet

	Period Ended	Fiscal Year Ended (Audited)
	Sep 30, 2024	Dec 31, 2023
Current Assets	5,410,947,634	5,135,417,492
Total Assets	10,954,272,478	10,763,917,993
Current Liabilities	3,859,441,892	3,918,103,074
Total Liabilities	4,874,651,502	4,918,730,015
Retained Earnings/(Deficit)	1,926,022,185	1,691,589,188
Stockholders' Equity	6,079,620,975	5,845,187,978
Stockholders' Equity - Parent	6,004,186,413	5,772,284,945
Book Value per Share	1.48	1.42

Income Statement

	Current Year (3 Months)	Previous Year (3 Months)	Current Year-To-Date	Previous Year-To-Date
Gross Revenue	1,562,885,817	1,134,872,447	4,070,273,865	3,273,889,174
Gross Expense	1,325,426,761	954,830,526	3,549,780,963	2,873,909,561
Non-Operating Income	4,568,608	3,201,211	14,639,613	12,873,723
Non-Operating Expense	79,049,975	62,172,077	224,050,787	187,697,378
Income/(Loss) Before Tax	162,977,690	121,071,055	311,081,729	225,155,958
Income Tax Expense	40,546,682	30,356,705	77,548,732	57,111,032
Net Income/(Loss) After Tax	122,431,007	90,714,350	233,532,996	168,044,926
Net Income Attributable to Parent Equity Holder	121,663,109	93,721,659	231,901,468	171,052,235
Earnings/(Loss) Per Share (Basic)	0.03	0.02	0.06	0.04
Earnings/(Loss) Per Share (Diluted)	0.03	0.02	0.06	0.04

	Current Year (Trailing 12 months)	Previous Year (Trailing 12 months)
Earnings/(Loss) Per Share (Basic)	0.06	0.04
Earnings/(Loss) Per Share (Diluted)	0.06	0.04

Other Relevant Information
None